Day: February 20, 2025

SYDNEY, Feb. 20, 2025 (GLOBE NEWSWIRE) — Axi, a leading global provider of online trading services, has proudly announced that trader Francisco Quesada Godines has reached the top milestone in its innovative capital allocation program, Axi Select, securing $1million in capital funding. This incredible achievement is a testament to the broker’s commitment to provide its Axi Select traders with a real opportunity to maximise their trading potential.

According to Greg Rubin, Head of Axi Select, “Francisco, has demonstrated exceptional talent and commitment to the program. This milestone extends far beyond receiving $1million in funding. It not only highlights what traders can achieve when they trade consistently and can seize market opportunities to their advantage, but it also underscores the power of an all-inclusive, trader-centric program designed to unlock traders’ full potential.”

“We are incredibly excited for this milestone–a testament to the hard work and dedication of our traders” said Rajesh Yohannan, CEO of Axi, as he shares his pride in their unique program. “When we launched Axi Select in 2023, our aim was clear: we wanted to change the narrative by creating a model that meets traders’ demands; when traders are free from upfront costs, restrictive trading conditions, and other barriers, they can focus exclusively on sharpening their trading performance. Indeed, our experience over the past year has demonstrated that, when a program is geared towards harnessing traders’ full potential, they can achieve remarkable results.”

Axi Select offers ambitious traders a pathway to access capital funding up to $1,000,000 USD and earn up to 90% of their profits, as well as the advantage to join the program with zero registration or monthly fees*. Moreover, Axi Select uses a Standard or a Pro live account, unrestrictive trading conditions, and a suite of tools to nurture traders’ success and growth.

*Standard trading fees apply.

The Axi Select program is only available to clients of AxiTrader Limited. CFDs carry a high risk of investment loss. In our dealings with you, we will act as a principal counterparty to all of your positions. This content is not available to AU, NZ, EU and UK residents. For more information, refer to our Terms of Service.

For more information contact : [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e3372dba-9460-4833-8180-ff68d3c17652

GlobeNewswire Distribution ID 1001049387

Fortrea to Sponsor SCRS’ Collaborate Forward Working Group, Encouraging Collaboration for More Efficient Clinical Trials

DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s sponsorship of the SCRS Collaborate Forward working group.

Comprising 16 leading Global Impact Partner organizations, the Collaborate Forward working group will explore and develop best practices to reduce administrative burdens across the clinical research ecosystem. The group is committed to fostering transparency and collaboration to tackle challenges faced by clinical research sites. By improving internal processes, it aims to make sites more sustainable and trials more efficient—ultimately leading to a smoother experience for patients.

Fortrea’s sponsorship marks a significant investment in fostering industry-wide innovation and reflects the company’s dedication to placing sites at the forefront of clinical trial planning.

“We are excited to partner with SCRS to launch and support this working group,” said Mike Clay, senior vice president of Global Project Delivery at Fortrea. “Clinical trials are becoming increasingly complex, and the industry faces mounting pressure to accelerate innovation for patients. We believe that collaboration with clinical research sites is key to unlocking efficiencies and productivity gains that will streamline the clinical trial process. This initiative will develop tangible solutions that clinical study sponsors, CROs, vendors, sites and patient advocacy groups can rally behind. As a leading CRO, we are proud to be at the forefront of this effort, ensuring that sites remain central to driving progress and fostering greater industry-wide collaboration to bring life-changing treatments to patients faster.”

“Clinical research requires a unique interdependency to generate the best outcomes. Collaborate Forward will share partnership successes that impact the people, process and technology improving clinical research today,” added Sean Soth, senior vice president, Strategy and Global Business Partnerships, SCRS. “We are pleased to welcome Fortrea as the charter sponsor of Collaborate Forward. This partnership underscores the value of cross-industry collaboration and the collective effort needed to drive meaningful progress in creating a more connected and efficient clinical trial ecosystem.”

Collaborate Forward will initially focus on study startup, showcasing the advantages of collaboration through compelling stories, case studies and data-driven insights. The group will convene regularly to exchange insights, assess industry trends and develop pragmatic tools that sponsors and CROs can implement within their organizations. Updates on the working group’s progress will be shared throughout 2025 via SCRS Site Solutions Summits and publications, highlighting key findings and collaborative achievements.

SCRS invites sponsors and CROs committed to site sustainability to join this effort and contribute to shaping a more effective and synergistic clinical research landscape. For more information on how to participate, please contact Brian Egan.

About The Society for Clinical Research Sites

The Society for Clinical Research Sites (SCRS) is the leading advocacy organization dedicated to unifying the voice of the global clinical research site community. Representing more than 11,000 research sites globally, SCRS facilitates industry collaborations and conversations dedicated to site-focused advocacy, education, mentorship and connection. SCRS is an active and influential champion for sites in industry initiatives to ensure that the perspective of sites is heard and valued. Learn more and get involved at myscrs.org. Our voice. Our community. Your success.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to customers globally. Learn more about how Fortrea is becoming a transformative force from pipeline to patient at Fortrea.com and follow us on LinkedIn and X (formerly Twitter).

SCRS Contacts:

Marissa Hill (Media) – 267-865-3296, [email protected]
Brian Egan (Media) – 518-207-6965, [email protected]

Fortrea Contacts:

Galen Wilson (Media) – 703-298-0802, [email protected]
Kate Dillon (Media) – 646-818-9115, [email protected]

GlobeNewswire Distribution ID 9361361